Other substances

Bictegravir

A HIV integrase inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

4
 Supporting references
0
 Contradictory references
3
 AI-suggested references
7
 Clinical trials

General information

Bictegravir is a human immunodeficiency virus (HIV) integrase inhibitor with limited use (LiverTox).

Bictegravir on DrugBank
Bictegravir on PubChem
Bictegravir on Wikipedia

Synonyms

GS-9883

Marketed as

With other drugs - BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)

 

Structure image - Bictegravir

C1C[C@@H]2C[C@H]1N3[C@H](O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F

Supporting references

Link Tested on Impact factor Notes Publication date
Systemic in Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server
in silico 4.55

Predicted to bind a SARS-CoV-2 protein structural feature.

 Aug/11/2020
Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
Preprint Screening 		in vitro

inhibitor of the ACE2-RBD interaction

 Jun/16/2020
Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein
Spike protein Small molecule In silico 		in silico 2.74

Predicted to bind SARS-CoV-2 Spike protein. The drug's "BD-2" derivative was predicted to have an enhanced capability to disrupt RBD binding to ACE2.

 Jan/25/2021
A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing
3CLpro Nucleocapsid protein nsp16 nsp10 Small molecule In silico 		in silico 2.74

Predicted to bind SARS-CoV-2 Nucleocapsid protein.

 Mar/18/2021

AI-suggested references

Link Publication date
Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase
Apr/20/2020
Virtual Screening FDA Approved Drugs against Multiple Targets of SARS-CoV-2
May/02/2021
Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection
Sep/08/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04890626 Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19 Recruiting Phase 3 Apr/04/2020 Nov/30/2022
  • Alternative id - PanCOVID
  • Interventions - Drug: Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA]|Drug: Baricitinib + dexamethasone|Drug: Dexamethasone
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Universitario La Paz, Madrid, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 2193
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Mortality
NCT04334928 Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel Completed Phase 3 Apr/15/2020 Jul/11/2021
  • Alternative id - PrEP COVID-19
  • Interventions - Drug: Emtricitabine/tenofovir disoproxil|Drug: Hydroxychloroquine|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo|Drug: Placebo: Hydroxychloroquine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Universitario de Ferrol, Ferrol, A Coruña, Spain|Hospital Clínico Universitario de Santiago, Santiago De Compostela, A Coruña, Spain|Hospital General de Elche, Elche, Alicante, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Sant Joan de Deu de Esplugues, Esplugues De Llobregat, Barcelona, Spain|Parc Sanitari Sant Joan de Déu de Sant Boi, Sant Boi De Llobregat, Barcelona, Spain|Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain|Hospital Infanta Margarita, Cabra, Córdoba, Spain|Hospital Insular de Las Palmas, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital Universitario de Canarias, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital de Donostia, San Sebastián, Guipuzcoa, Spain|Hospital San Pedro, Logroño, La Rioja, Spain|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Hospital Fundación de Alcorcón, Alcorcón, Madrid, Spain|Hospital Colllado Villalba, Collado-Villalba, Madrid, Spain|Hospital de Getafe, Getafe, Madrid, Spain|Hospital Severo Ochoa, Leganés, Madrid, Spain|Hospital de Móstoles, Móstoles, Madrid, Spain|Hospital Rey Juan Carlos, Móstoles, Madrid, Spain|Hospital Quirón Pozuelo, Pozuelo De Alarcón, Madrid, Spain|Hospital de Torrejón, Torrejón De Ardoz, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Hospital Virgen del Castillo, Yecla, Murcia, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Reina Sofía, Tudela, Navarra, Spain|Hospital Arnau de Vilanova, Llíria, Valencia, Spain|Hospital de Araba, Alava, Vitoria, Spain|Hospital General Universitario de Albacete, Albacete, Spain|Centro Médico Teknon, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Dexeus, Barcelona, Spain|Hospital Quirón Barcelona, Barcelona, Spain|Hospital Universitario Sagrat Cor, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Hospital Clínico San Cecilio, Granada, Spain|Hospital Universitario de León, León, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Reina Sofía, Murcia, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital Clinico Universitario, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital de Valladolid, Valladolid, Spain|Hospital Rio Hortega, Valladolid, Spain|Hospital Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Hospital Nuestra Señora de Sonsoles, Ávila, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 1002
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)|Severity of disease in confirmed infected participants of SARS-CoV-2 (COVID-19)|Duration of symptoms in confirmed infected participants of SARS-CoV-2 (COVID-19) measured in days
NCT04712357 Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19 Recruiting Not Applicable Nov/09/2020 Jan/01/2023
  • Alternative id - CAAE: 34182620.0.0000.5045
  • Interventions - Drug: Vitamin C 500 MG Oral Tablet|Drug: Tenofovir disoproxyl fumarate 300 MG Oral Tablet|Drug: Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Núcleo de Biomedicina - NUBIMED, Fortaleza, Ceará, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 219
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - The time to recovery, defined at day 7 days follow up after enrollment, on which a patient met the criteria for category 1, 2, or 3 on the eight-category ordinal scale.|SARS-CoV-2 RNA viral load measurements change.|Proportion of patients with qualitative serum IgM / IgG.|Biomarkers (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-α, MCP-1, IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I, CRP and procalcitonin) measurements change.
NCT04359095 Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia Completed Phase 2|Phase 3 Aug/18/2020 Jun/30/2021
  • Alternative id - 76968
  • Interventions - Drug: Emtricitabine/tenofovir|Drug: Colchicine Pill|Drug: Rosuvastatin|Other: Standard treatment
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Clinica santa Maria del lago, Bogota, DC, Colombia|Clínica Reina Sofía, Bogotá, Colombia|Fundacion Cardio Infantil, Bogotá, Colombia|Hospital Universitario San Ignacio, Bogotá, Colombia|Clinica Universitaria Colombia, Bogotá, Colombia|Hospital Universitario Nacional de Colombia, Bogotá, Colombia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 650
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection
NCT04685512 Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home Completed Phase 2|Phase 3 Nov/18/2020 May/01/2021
  • Alternative id - 20-070
  • Interventions - Drug: tenofovir disoproxil and emtricitabine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Caen University Hospital, Caen, Calvados, France|Regional Hospital, Orléans, France
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Phase 2B: Reduction of SARS-CoV2 viral load assessed by Ct PCR at day-4 adjusted on Ct PCR SARS-CoV2 viral load at baseline (ANCOVA)|Phase 3: Rate of non-contagious nasopharyngeal sample for SARS-CoV2 by PCR on Day-4 with Ct > or = 28|Phase 2B/3: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Phase 3: Symptoms score|Phase 3: Proportion of secondary hospitalization|Phase 3: Rate of non-contagious nasopharyngeal sample for SARS-CoV2 by PCR on Day-7 with Ct > or = 28
NCT04519125 Daily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia Not yet recruiting Phase 2|Phase 3 Aug/30/2020 Apr/01/2021
  • Alternative id - 2020 /143|77389
  • Interventions - Drug: Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)|Other: Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  • Enrollment - 950
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - SARS-CoV-2 infection|Serious and non-serious adverse events|Discontinuation of using TDF/FTC for any reason|Adherence to TDF/FTC|Severity of SARS-CoV-2 infection
NCT04405271 TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study) Not yet recruiting Phase 3 Jul/31/2020 Nov/15/2020
  • Alternative id - 5616
  • Interventions - Drug: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Sociedad Argentina de Infectología, A. J. Carranza 974, Ciudad Autonoma de Buenos Aires, Capital Federal, Argentina
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 1378
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - COVID-19 incident cases|Number of asymptomatic SARS-CoV-2 (Covid-19) infections confirmed by serology|Severity of symptomatic COVID-19|Respiratory symptom duration in days|Relation between treatments and symptoms duration|Time course of specific IgM/IgG seroconversion
Export (.csv)